Phase Forward Teams with PharmaNet Development Group

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with PharmaNet Development Group, Inc., a global drug development services company, that enables PharmaNet to offer Phase Forward's InForm(TM) electronic data capture (EDC) solution to PharmaNet customers worldwide. PharmaNet provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries that includes clinical trial data management.

"We chose to team with Phase Forward on the basis of our successful collaboration on behalf of several pharmaceutical companies," said Thomas Newman, M.D., President, PharmaNet Late Stage Development. "That experience indicated the complementary nature of Phase Forward's established leadership in EDC technology solutions and our expertise in providing clinical trial services to a broad range of industries. We look forward to extending to other customers the success our work together has already achieved."

"Customers are turning to PharmaNet for its proven expertise in providing the critical services infrastructure required to optimize the clinical trial process," said Steve Powell, senior vice president, Phase Forward. "Our InForm EDC solution is a perfect addition to PharmaNet's expertise and we look forward to building on and expanding our work together."

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, demand for Phase Forward's products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward's customers to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, the possibility that customers' needs or plans may change over time, the possibility that the level of demand for Phase Forward's products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

SOURCE: Phase Forward

Phase Forward 
Elaine Maynard, 781-902-4371 
elaine.maynard@phaseforward.com 
or 
CHEN PR, Inc. 
Randy Wambold, 781-672-3119 
rwambold@chenpr.com

Related terms: annual report, biotechnology, business, cancer, clinical, consulting, fda, healthcare, knowledge management, medical, nasdaq, pharmaceuticals, president, products, research, securities, technology, trial